Kalaris Therapeutics, Inc. (KLRS)
9.13
-1.29
(-12.38%)
USD |
NASDAQ |
Dec 19, 16:00
9.41
+0.28
(+3.07%)
After-Hours: 06:37
Kalaris Therapeutics Shareholders Equity (Quarterly): 41.86M for Sept. 30, 2025
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| CEL-SCI Corp. | 7.025M |
| AIM ImmunoTech, Inc. | -6.077M |
| IGC Pharma, Inc. | 8.092M |
| NovaBay Pharmaceuticals, Inc. | 1.634M |
| Protalix Biotherapeutics, Inc. | 52.91M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 81.18M |
| Total Liabilities (Quarterly) | 39.31M |
| Debt to Equity Ratio | 0.0369 |
| Current Ratio | 12.89 |
| Net Debt Paydown Yield | 1.38% |